JNJ's REMICADE Holds: PFE's Results To Confirm
Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (referenceĀ product for...
617 Views
Olympus--Dead Money for Momentum Investors; Dip-Buying Time for Long-Term Investors
Olympus generates 98% of its profits from endoscopes sales and has a 70% global share of gastro enteral endoscope systems. Their current line-up is...
411 Views
Actelion / Johnson & Johnson: Tendered Vs Untendered Lines
Any deal-threatening risks to the Actelion / Johnson & Johnson transaction were assuaged in late March and we now solely await EC antitrust...
430 Views
The Week That Was in NorthAsia@Smartkarma - THAAD Deployment, Mobile Lineage, and Activism in Japan
KoreaScott Laprise/ ä¹å¤©č and Prasenjit K. Basu have provided great insights regarding the political turmoil surrounding North Korea. Scott makes it...
401 Views
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
706 Views